Product Details
Crizotinib for Tablets BP
Product Name
:
Crizotinib for Tablets BP
Brand Name
:
VERCRIZ
Available Strength
:
250 mg
Packing
:
60 Tablets
Pack Insert/Leaflet
:
According To Your Needs
These film-coated tablets meet British Pharmacopoeia standards, supporting targeted treatment for ALK-positive non-small cell lung cancer. Oncologists prescribe Crizotinib for patients whose tumors test positive for ALK or ROS1 gene rearrangements.
Crizotinib BP (250 mg) is a tyrosine kinase inhibitor that blocks ALK and ROS1 signaling, interrupting the growth pathway driving these tumors. As a result, it helps control tumor progression in eligible patients. Because of this targeted mechanism, oncology specialists prescribe it under close supervision as part of an individualized treatment plan. Therefore, hospitals and oncology clinics restrict its use to patients under specialist care.
Key Features
- Meets BP (British Pharmacopoeia) standards for consistent quality
- Delivers targeted ALK/ROS1 inhibition for lung cancer therapy
- Ensures accurate, validated dosing in every batch
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncologist supervision
- Restricted to hospital, oncology clinic, and specialist institutional supply